Molybdenum Cofactor Deficiency
Autozomálně recesivní
A condition caused by changes in both copies of MOCS1, MOCS2 or GPHN, which are needed to make the molybdenum cofactor used by sulfite oxidase and other enzymes.
Co se diagnózou změní
Fosdenopterin is an approved treatment for type A (MOCS1) and works best when started very early; carrier status is relevant to family planning.
Známé také jako
combined deficiency of sulfite oxidase, xanthine dehydrogenase and aldehyde oxidase; MOCOD
Zahrnuje 4 příbuzných podtypů ↓Skrýt podtypy ↑
- sulfite oxidase deficiency due to molybdenum cofactor deficiency type A
- sulfite oxidase deficiency due to molybdenum cofactor deficiency type B1
- sulfite oxidase deficiency due to molybdenum cofactor deficiency type B2
- sulfite oxidase deficiency due to molybdenum cofactor deficiency type C
